Research News
View articles by month and year
11–20 of 20 articles
-
Giving Chemo Medicines Sequentially May Have Advantages
Treating early-stage breast cancer with two chemotherapy medicines followed by a third seems to have some advantages compared to giving two or three medicines at the same time, but may cause more severe side effects.
-
Herceptin Plus Chemotherapy Without Anthracycline Effective
The latest results from the BCIRG-006 trial found that Herceptin plus chemotherapy that didn't include an anthracycline was as effective as Herceptin plus chemotherapy that did include an anthracycline for women diagnosed with HER2-positive, early-stage breast cancer.
-
Research Continues to Show Benefit of Chemotherapy After Breast Cancer Surgery
Research suggests that post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer that had spread to the lymph nodes who got adjuvant chemotherapy AND adjuvant hormonal therapy had a lower risk of recurrence and were more likely to be alive than women who got only hormonal therapy. The study also showed that starting hormonal therapy after chemotherapy was done was better than giving hormonal therapy and chemotherapy at the same time and that a genetic test can help figure out if women diagnosed with early-stage, hormone-receptor-positive breast cancer that has spread to the lymph nodes will benefit from adjuvant chemotherapy.
-
Older Women Do Better on Conventional Chemo Compared to Xeloda
Research shows that women older than 65 do better on standard intravenous chemotherapy after surgery to remove early-stage breast cancer than Xeloda (chemical name: capecitabine), an oral chemotherapy.
-
HER2 and Topo II Status Affects Response to Anthracycline Chemo
A new study suggests that anthracycline-based chemotherapy regimens should be used to treat only HER2-positive breast cancers.
-
New Chemo Meds Improve Survival for Women with Advanced-Stage Disease
Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.
-
Cancers Resistant to Anthracyclines May Respond to Taxotere-Xeloda Combo
A new study suggests that breast cancer that is resistant to an anthracycline may respond to a combination of two other chemotherapies, Taxotere (chemical name: docetaxel) and Xeloda (chemical name: capecitabine).
-
Taxol Weekly Better Than Every Three Weeks for Breast Cancer
Getting Taxol (chemical name: placlitaxel) every week seems to have more benefits than getting it every 3 weeks or getting Taxotere (chemical name: docetaxel) on either schedule.
-
Taxotere Combo Improves Survival
The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.
-
Some Women Don’t Benefit from Adding Taxol to Chemo Regimen
An early breast cancer's HER2 status affects the benefits offered by Taxol.
11–20 of 20 articles
